Ocriplasmin approved for treatment of symptomatic vitreomacular adhesion | Ophthalmology

[ad_1]
Ocriplasmin approved for treatment of symptomatic vitreomacular adhesion

Ocriplasmin approved for treatment of symptomatic vitreomacular adhesion | Ophthalmology

Ophthalmology | The U.S. Food and Drug Administration has approved Jetrea to treat symptomatic vitreomacular adhesion, according to a news release from ThromboGenics. The approval follows a phase 3 program in which Jetrea (ocriplasmin) was superior to placebo for the treatment of symptomatic vitreo…
[ad_2]

Return to main website.